Literature DB >> 26238722

Live attenuated Salmonella enterica serovar Choleraesuis vaccine vector displaying regulated delayed attenuation and regulated delayed antigen synthesis to confer protection against Streptococcus suis in mice.

Zhenying Ji1, Jing Shang1, Yuan Li1, Shifeng Wang2, Huoying Shi3.   

Abstract

Salmonella enterica serotype Choleraesuis (S. Choleraesuis) and Streptococcus suis (S. suis) are important swine pathogens. Development of a safe and effective attenuated S. Choleraesuis vaccine vector would open a new window to prevent and control pig diseases. To achieve this goal, the mannose and arabinose regulated delayed attenuated systems (RDAS), Δpmi and ΔPcrp::TT araC PBADcrp, were introduced into the wild type S. Choleraesuis strain C78-3. We also introduced ΔrelA::araC PBADlacI TT to achieve regulated delayed antigen synthesis and ΔasdA to constitute a balanced-lethal plasmid system. The safety and immunogenicity of the resulted RDAS S. Choleraesuis strain rSC0011 carrying 6-phosphogluconate dehydrogenase (6-PGD) of S. suis serotype 2 (SS2) were evaluated in vitro and in vivo. Compared with the wild type parent strain C78-3 and vaccine strain C500, a live attenuated S. Choleraesuis vaccine licensed for piglet in China, the results showed that the survival curves of the vaccine strain rSC0011 were similar to those of strains C78-3 and C500 at the early stage of infection, but lower than those of C78-3 and higher than those of C500 at the later stage in both porcine alveolar macrophages and peripheral porcine monocytes. The LD50 of the RDAS strains rSC0011 by oral route in mice was close to that of C500 and 10,000-fold higher than that of C78-3. Similar results were achieved by intraperitoneal (i.p.) route, suggesting that the RDAS strains rSC0011 achieved similar attenuation as C500. However, the RDAS strain rSC0011 was superior to C500 in colonization of Peyer's patches. Adult mice orally immunized with strain rSC0011 carrying a plasmid expression 6-phosphogluconate dehydrogenase (6-PGD) gene from SS2 developed strong immune responses against 6-PGD and Salmonella antigens, and conferred high protection against i.p. challenge with SS2.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  6-PGD; Regulated delayed antigen synthesis; Regulated delayed attenuation system; Salmonella Choleraesuis; Streptococcus suis

Mesh:

Substances:

Year:  2015        PMID: 26238722     DOI: 10.1016/j.vaccine.2015.07.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Salmonella enterica serovar Choleraesuis vector delivering a dual-antigen expression cassette provides mouse cross-protection against Streptococcus suis serotypes 2, 7, 9, and 1/2.

Authors:  Yu-An Li; Yanni Sun; Yang Fu; Yuqin Zhang; Quan Li; Shifeng Wang; Huoying Shi
Journal:  Vet Res       Date:  2022-06-22       Impact factor: 3.829

2.  Live-attenuated Salmonella enterica serotype Choleraesuis vaccine with regulated delayed fur mutation confer protection against Streptococcus suis in mice.

Authors:  Yu-An Li; Yunyun Chen; Yuan Zhao Du; Weiwei Guo; Dianfeng Chu; Juan Fan; Xiaobo Wang; Matthew Bellefleur; Shifeng Wang; Huoying Shi
Journal:  BMC Vet Res       Date:  2020-05-07       Impact factor: 2.741

3.  The role of TolA, TolB, and TolR in cell morphology, OMVs production, and virulence of Salmonella Choleraesuis.

Authors:  Quan Li; Zheng Li; Xia Fei; Yichen Tian; Guodong Zhou; Yuhan Hu; Shifeng Wang; Huoying Shi
Journal:  AMB Express       Date:  2022-01-25       Impact factor: 3.298

4.  Salmonella enterica serovar Choleraesuis vector delivering SaoA antigen confers protection against Streptococcus suis serotypes 2 and 7 in mice and pigs.

Authors:  Yu-An Li; Zhenying Ji; Xiaobo Wang; Shifeng Wang; Huoying Shi
Journal:  Vet Res       Date:  2017-12-21       Impact factor: 3.683

5.  Attenuated Salmonella enterica Serovar Typhimurium, Strain NC983, Is Immunogenic, and Protective against Virulent Typhimurium Challenges in Mice.

Authors:  Bryan Troxell; Mary Mendoza; Rizwana Ali; Matthew Koci; Hosni Hassan
Journal:  Vaccines (Basel)       Date:  2020-11-03
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.